Targeted nuclear therapy, delivered with precision.
From radioiodine for hyperthyroidism and thyroid cancer to next-generation Lutetium-177 & FAPI therapies — every treatment plan is personalized and safety-monitored.
Our Nuclear Therapy Services
Click on any therapy card below to explore full clinical details, preparation guidelines, and step-by-step procedure timelines.
I-131 Radioiodine Therapy (10 mCi) for Hyperthyroidism
Low-dose I-131 therapy for Graves' disease, toxic multinodular goitre and autonomous thyroid nodules.
I-131 Radioiodine Therapy – 30 mCi
Standard-dose radioactive iodine for post-surgical thyroid remnant ablation in low-risk differentiated thyroid cancer.
I-131 Radioiodine Therapy – 50 mCi
Intermediate-dose RAI for intermediate-risk thyroid cancer or cases with incomplete remnant ablation.
I-131 Radioiodine Therapy – 100 mCi
High-dose RAI for high-risk differentiated thyroid cancer with confirmed lymph node involvement or local invasion.
I-131 Radioiodine Therapy – 200 mCi
Maximum-dose RAI for metastatic differentiated thyroid cancer with distant spread to lungs or bones.
FAPI THERAPY
Fibroblast Activation Protein Inhibitor (FAPI) targeted radionuclide therapy for fibroblast-rich solid tumours.
¹⁷⁷Lu-DOTA therapy – 150 to 200 mCi
Lutetium-177 DOTATATE peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours (NETs).
¹⁷⁷Lu-PSMA therapy – 150 to 200 mCi
Lutetium-177 PSMA radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC).
What to expect, step by step.
Radiation safety, taken seriously.
Dosing, isolation and post-therapy monitoring follow international nuclear medicine standards. Every patient receives a personalized safety plan.
Post-therapy, you receive clear, written household guidance so returning home feels safe and simple — for you and everyone around you.
Thyroglobulin tracking, post-therapy scans, regular lab work and long-term monitoring — nothing is left to chance.